Somatic EGFR mutations are detected in 10% to 16% of NSCLC patients in the United States and Europe [4] and 30% to 50% of those in Asia [5], with ~90% presenting as deletions in exon 19, most commonly the E746_A750 deletion, and an L858R substitution in exon 21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.